Kim Kyung-Jin, Cho Hyun-Jai, Kim Min-Seok, Kang Jeehoon, Kim Kyung-Hee, Kim Darea, Seo Suk Min, Yang Jeong Hoon, Cha Myung-Jin, Choi Jong Il, Choi Dong-Ju
Division of Cardiology, Department of Internal Medicine, Ewha Womans University Medical Center, Ewha Womans University School of Medicine, Seoul, Korea.
Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Int J Heart Fail. 2019 Oct 8;1(1):4-24. doi: 10.36628/ijhf.2019.0002. eCollection 2019 Oct.
The incidence of heart failure (HF) is increasing in South Korea and devising the optimal care plan is crucial to promote appropriate and effective treatment of HF. To this end, the first Korean guideline for management of chronic HF was published in 2016 by the HF research group under the Korean Society of Cardiology (KSC). After this publication, considerable data have been accumulated and a new guideline for the management of HF was published in Europe, and an update regarding pharmacological therapy was published in the United States, which made it warrant to update the Korean guideline. Under this premise, The Clinical Practice Guidelines Committee under the Korean Society of Heart Failure (KSHF) founded in 2018 decided to publish a focused update management guideline for chronic HF and selected 15 topics that need an update regarding the diagnosis, definition, diagnostic algorithm, monitoring, novel biomarkers, drug therapy related to non-vitamin K antagonist oral anticoagulants and angiotensin receptor neprilysin inhibitors, and with respect to comorbidities changes in the guidelines of relevant institutions, such as new guidelines for the management of hypertension, a procedure used to treat severe aortic stenosis, information on sodium glucose co-transporter-2 inhibitor, and that about sleep apnea. Among nonpharmacological therapies, changes to the recommendations for implantable cardioverter defibrillator, cardiac resynchronization therapy, and cardiac rehabilitation were updated. Subsequent and continuous updates based on additional clinical research findings, with continual supervision by the KSHF will be needed.
心力衰竭（HF）在韩国的发病率呈上升趋势，制定最佳护理计划对于促进HF的恰当有效治疗至关重要。为此，韩国心脏病学会（KSC）下属的HF研究小组于2016年发布了首部韩国慢性HF管理指南。该指南发布后，积累了大量数据，欧洲发布了新的HF管理指南，美国发布了药物治疗方面的更新内容，这使得更新韩国指南成为必要。在此前提下，2018年成立的韩国心力衰竭学会（KSHF）临床实践指南委员会决定发布一份慢性HF重点更新管理指南，并选定了15个需要更新的主题，涉及诊断、定义、诊断算法、监测、新型生物标志物、与非维生素K拮抗剂口服抗凝药和血管紧张素受体脑啡肽酶抑制剂相关的药物治疗，以及相关机构指南中的合并症变化，如高血压管理新指南、治疗严重主动脉瓣狭窄的程序、钠葡萄糖协同转运蛋白2抑制剂信息以及睡眠呼吸暂停相关信息。在非药物治疗方面，对植入式心脏复律除颤器、心脏再同步治疗和心脏康复的推荐也进行了更新。后续需要根据更多临床研究结果进行持续更新，并由KSHF持续监督。
